<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01101906</url>
  </required_header>
  <id_info>
    <org_study_id>OSI-906-206</org_study_id>
    <secondary_id>2010-018739-17</secondary_id>
    <nct_id>NCT01101906</nct_id>
  </id_info>
  <brief_title>A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC</brief_title>
  <official_title>A Randomized, Placebo-controlled, Double-blinded Phase 2 Study of Second-line Treatment With OSI-906 in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure of First-line Treatment With Sorafenib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled, double-blind phase 2 study of OSI-906 or placebo at&#xD;
      a continuous 150 mg twice daily (BID) dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult patients with advanced HCC previously treated with sorafenib will be randomized 2:1 to&#xD;
      receive either single agent OSI-906 or placebo&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Company decided not to pursue the development of this drug in this patient population at this&#xD;
    time&#xD;
  </why_stopped>
  <start_date type="Actual">January 10, 2011</start_date>
  <completion_date type="Actual">December 28, 2011</completion_date>
  <primary_completion_date type="Actual">November 4, 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>20 months</time_frame>
    <description>Time from randomization to radiological disease progression based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>23 months</time_frame>
    <description>Date of randomization until the documented date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>23 months</time_frame>
    <description>Time from randomization to radiological disease progression based on RECIST version 1.1 assessed by investigator or death due to any cause whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (including clinical progression) (TTPc)</measure>
    <time_frame>23 months</time_frame>
    <description>Time from randomization to progression (either radiological disease progression based on RECIST version 1.1 or symptomatic clinical progression as assessed by investigator)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>23 months</time_frame>
    <description>Proportion of patients with a best overall response of complete response (CR), partial response (PR), or stable disease based on RECIST version 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>23 months</time_frame>
    <description>Proportion of patients with a best overall response of CR or PR based on RECIST version 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression in patients with hepatitis B virus (HBV) and/or hepatitis C virus (HVC)</measure>
    <time_frame>23 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival in patients with HBV and/or HCV</measure>
    <time_frame>23 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival in patients with HBV and/or HCV</measure>
    <time_frame>23 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate in patients with HBV and/or HCV</measure>
    <time_frame>23 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed via physical examination, vital signs, clinical laboratory tests, electrocardiograms (ECGs) and recording adverse events</measure>
    <time_frame>23 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Advanced Hepatocellular Carcinoma (HCC)</condition>
  <arm_group>
    <arm_group_label>Arm A: OSI-906</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OSI-906</intervention_name>
    <description>OSI-906 administered orally</description>
    <arm_group_label>Arm A: OSI-906</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo administered orally</description>
    <arm_group_label>Arm B: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of advanced HCC. Clinical diagnosis by American&#xD;
             Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic patients is&#xD;
             acceptable. For patients without cirrhosis histological confirmation is mandatory&#xD;
&#xD;
          -  Patients must have received prior systemic treatment for advanced HCC with sorafenib&#xD;
             and had confirmed disease progression or had discontinued sorafenib due to a drug&#xD;
             related toxicity&#xD;
&#xD;
          -  Patient has received their last dose of sorafenib at least 14 days prior to&#xD;
             randomization&#xD;
&#xD;
          -  Patient has recovered from sorafenib or investigational agent related toxicity to ≤&#xD;
             grade 2&#xD;
&#xD;
          -  Measurable disease according to RECIST (version 1.1)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 - 1&#xD;
&#xD;
          -  Child-Pugh Status A or B(7)&#xD;
&#xD;
          -  Barcelona Clinic Liver Cancer (BCLC) stage B/C&#xD;
&#xD;
          -  Previous local therapy (eg, surgery, radiation therapy, hepatic arterial therapy,&#xD;
             chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or&#xD;
             cryoablation) is permitted if ≥ 21 days before randomization&#xD;
&#xD;
          -  Fasting glucose ≤ 150 mg/dL (8.3 mmol/L). Concurrent use of non-insulinotropic oral&#xD;
             antihyperglycemic therapy is permitted if the dose has been stable for ≥ 4 weeks at&#xD;
             the time of randomization&#xD;
&#xD;
          -  Following laboratory parameters (determined by laboratory):&#xD;
&#xD;
               -  Platelets ≥ 60 x 10^9/L&#xD;
&#xD;
               -  Hemoglobin ≥ 8.5 g/dL&#xD;
&#xD;
               -  Absolute neutraphil count (ANC) ≥ 1.5 x 10^9/L&#xD;
&#xD;
               -  Potassium within normal limits (supplementation may be used)&#xD;
&#xD;
               -  Partial thrombopastin time (PTT) ≤ 2.3 x Upper Limit of Normal (ULN)&#xD;
&#xD;
               -  Magnesium within normal limits (supplementation may be used)&#xD;
&#xD;
               -  Calcium within normal limits (supplementation may be used)&#xD;
&#xD;
          -  Adequate organ function (for a HCC population):&#xD;
&#xD;
               -  Liver function test (LFT) ≤ 5 x ULN&#xD;
&#xD;
               -  Albumin ≥ 2.8 g/dL&#xD;
&#xD;
               -  Total bilirubin ≤ 2.8 mg/dL&#xD;
&#xD;
               -  Creatinine ≤ 1.5 x ULN&#xD;
&#xD;
               -  International normalized ratio (INR) ≤ 2.3&#xD;
&#xD;
          -  Estimated life expectancy ≥ 12 weeks based on an investigator assessment of recent&#xD;
             changes in laboratory values, performance status, and other clinical criteria&#xD;
&#xD;
          -  Patients, both males and females, with reproductive potential (ie, menopausal for less&#xD;
             than 1 year and not surgically sterilized) must agree to practice effective&#xD;
             contraceptive measures throughout the study. Women of childbearing potential must&#xD;
             provide a negative pregnancy test (serum or urine) within 14 days prior to&#xD;
             randomization&#xD;
&#xD;
          -  Patients must provide written informed consent to participate in the study&#xD;
&#xD;
          -  Prior radiation therapy is permitted provided patients have recovered from the acute,&#xD;
             toxic effects of radiotherapy prior to randomization. A minimum of 21 days must have&#xD;
             elapsed between the end of radiotherapy and randomization; and&#xD;
&#xD;
          -  Prior surgery is permitted provided that the surgery was done ≤ 28 days prior to&#xD;
             randomization and adequate wound healing has occurred prior to randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Child-Pugh B (8 - 9) or C&#xD;
&#xD;
          -  Patients who are candidates for potentially curative intervention (ie, surgical&#xD;
             resection or transplantation)&#xD;
&#xD;
          -  Type 1 diabetes mellitus or Type 2 diabetes mellitus currently requiring&#xD;
             insulinotropic or insulin therapy&#xD;
&#xD;
          -  Prior insulin-like growth factor - 1 receptor (IGF-1R) therapy&#xD;
&#xD;
          -  Patients requiring interferon&#xD;
&#xD;
          -  Patients with uncontrolled symptomatic ascites&#xD;
&#xD;
          -  Prior investigational agent within 21 days prior to randomization&#xD;
&#xD;
          -  History of poorly controlled gastrointestinal disorders that could affect the&#xD;
             absorption of study drug (eg, Crohn's disease, ulcerative colitis, etc)&#xD;
&#xD;
          -  History of organ allograft including liver transplant&#xD;
&#xD;
          -  Malignancy other than HCC within the past 3 years:&#xD;
&#xD;
               -  Exceptions: resected basal cell or squamous cell carcinoma of the skin, cured in&#xD;
                  situ cervical carcinoma, cured ductal carcinoma in situ of the breast, and/or&#xD;
                  cured superficial bladder cancer&#xD;
&#xD;
          -  History (within last 6 months) of significant cardiovascular disease unless the&#xD;
             disease is well-controlled. Significant cardiac disease includes second/third degree&#xD;
             heart block; clinically significant ischemic heart disease; superior vena cava (SVC)&#xD;
             syndrome; poorly controlled hypertension; congestive heart failure of New York Heart&#xD;
             Association (NYHA) Class II or worse (slight limitation of physical activity;&#xD;
             comfortable at rest, but ordinary physical activity results in fatigue, palpitation,&#xD;
             or dyspnea)&#xD;
&#xD;
          -  History of arrhythmia (multifocal premature ventricular contractions [PVCs], bigeminy,&#xD;
             trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) that is&#xD;
             symptomatic or requires treatment (≥ grade 3), left bundle branch block (LBBB), or&#xD;
             asymptomatic sustained ventricular tachycardia are not allowed. Patients with atrial&#xD;
             fibrillation controlled by medication are not excluded&#xD;
&#xD;
          -  QTcF interval at screening ≥ 450 msec&#xD;
&#xD;
          -  Use of drugs that have a known risk of causing Torsades de Pointes (TdP) ('Torsades&#xD;
             List' on www.azcert.org/medical-pros/drug-lists/by category.cfm)are prohibited within&#xD;
             14 days prior to randomization&#xD;
&#xD;
          -  Use of the potent CYP1A2 inhibitors ciprofloxacin and fluvoxamine. Other less potent&#xD;
             CYP1A2 inhibitors/inducers are not excluded&#xD;
&#xD;
          -  History of cerebrovascular accident (CVA) within 6 months prior to randomization or&#xD;
             that resulted in ongoing neurologic instability&#xD;
&#xD;
          -  Active infection or serious underlying medical condition (including any type of active&#xD;
             seizure disorder within 12 months prior to randomization) that would impair the&#xD;
             ability of the patient to receive study drug&#xD;
&#xD;
          -  History of human immunodeficiency virus (HIV) infection or acquired immune deficiency&#xD;
             syndrome (AIDS)-related illness or serious acute or chronic illness&#xD;
&#xD;
          -  History of any psychiatric or neurologic condition that might impair the patient's&#xD;
             ability to understand or to comply with the requirements of the study or to provide&#xD;
             informed consent&#xD;
&#xD;
          -  Pregnant or breast-feeding females&#xD;
&#xD;
          -  Symptomatic brain metastases that are not stable, require steroids, are potentially&#xD;
             life threatening, or that have required radiation within 28 days prior to&#xD;
             randomization; and/or&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California - Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University Health Services Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>52336</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussells</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Jean Verdier - Dervice d'Hepato-Gastroenterologie</name>
      <address>
        <city>Bondy Cedex</city>
        <zip>93143</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Creteil cedex</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de la Timone</name>
      <address>
        <city>Marseille Cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital l'Archet 2</name>
      <address>
        <city>Nice cedex 03</city>
        <zip>6202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Antoine</name>
      <address>
        <city>Paris cedex 12</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Tenon</name>
      <address>
        <city>Paris cedex 12</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Gauducheau</name>
      <address>
        <city>Saint Herblain cedex</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle</name>
      <address>
        <city>Halle</city>
        <zip>06097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg A.ö.R.</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Ca' Granda Ospedale Maggiore Policlinico, Divisione di Gastroenterologia I</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Fatebenefratelli, Dipartimento Medicina Interna</name>
      <address>
        <city>Napoli</city>
        <zip>80123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Nazionale per lo studio e la cura dei tumori Fondazione G. Pascale-SSD Epatobiliare</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione ISMETT-Dipartimento di Epatologia e Gastroenterologia</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-774</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Singapore International Medical Centre</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Coruna</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro Majadahonda</name>
      <address>
        <city>Madrid</city>
        <zip>28220</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation LinKou Branch</name>
      <address>
        <city>TaoYuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://astellasclinicalstudyresults.com/study.aspx?ID=228</url>
    <description>Link to results on the Astellas Clinical Study Results website.</description>
  </link>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>April 8, 2010</study_first_submitted>
  <study_first_submitted_qc>April 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2010</study_first_posted>
  <disposition_first_submitted>December 10, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>December 10, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 12, 2012</disposition_first_posted>
  <last_update_submitted>August 31, 2018</last_update_submitted>
  <last_update_submitted_qc>August 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCC</keyword>
  <keyword>OSI-906</keyword>
  <keyword>Hepatocellular Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under &quot;Sponsor Specific Details for Astellas.&quot;</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

